A Randomized, Double-Blind, Two-Arm Placebo-Controlled, Parallel-Group, Multicenter Study of Rimonabant 20 mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdominally Obese Patients.

Trial Profile

A Randomized, Double-Blind, Two-Arm Placebo-Controlled, Parallel-Group, Multicenter Study of Rimonabant 20 mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdominally Obese Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2012

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Atherosclerosis; Dyslipidaemias; Lipid metabolism disorders; Obesity
  • Focus Pharmacodynamics; Registrational
  • Acronyms ADAGIO-LIPIDS
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Apr 2009 Actual initiation date changed from Jun 2005 to May 2005 as reported by ClinicalTrials.gov.
    • 01 Mar 2009 Results published in Arteriosclerosis and Thrombosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top